{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 459829456
| IUPAC_name = 3-Methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
| image = Nilvadipine structure.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|nilvadipine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL         / P       / POM / CD -->
| legal_US = <!-- OTC                   / Rx-only  -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATC_prefix = C08
| ATC_suffix = CA10
| PubChem = 4494
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06712
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0214FUT37J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01908
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 517427
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 4338


<!--Chemical data-->
| C=19 | H=19 | N=3 | O=6 
| molecular_weight = 385.370 g/mol
| smiles            = CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = FAIIFDPAEUKBEP-UHFFFAOYSA-N
}}

'''Nilvadipine''' is a [[calcium channel blocker]] (CCB) used for the treatment of [[hypertension]] and chronic major cerebral artery [[Vascular occlusion|occlusion]]. 

Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.

Nilvadipine was tested in clinical trial as a possible treatment for [[Alzheimer's Disease]] in Ireland by the [[Roskamp Institute]], Florida, USA and Trinity College, Ireland.<ref>[http://www.rfdn.org/news_release_090806_faq.html Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Questions and Answers<!-- Bot generated title -->]</ref> 

Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of nilvadipine. More than 500 Alzheimerâ€™s patients will participate in the multicenter phase III clinical trial designed to study the effectiveness of nilvadipine.<ref>[http://www.rfdn.org/news_release_052511.html Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Press Release <!-- Bot generated title -->]</ref>

==References==
{{Reflist}}

{{Ion channel modulators}}
{{Xenobiotic-sensing receptor modulators}}

[[Category:Calcium channel blockers]]
[[Category:Dihydropyridines]]
[[Category:Nitriles]]
[[Category:Nitrobenzenes]]
[[Category:Carboxylate esters]]


{{Cardiovascular-drug-stub}}